AR089085A1 - Anticuerpos dirigidos al receptor de factor de crecimiento epidermico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3 - Google Patents

Anticuerpos dirigidos al receptor de factor de crecimiento epidermico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3

Info

Publication number
AR089085A1
AR089085A1 ARP120104559A ARP120104559A AR089085A1 AR 089085 A1 AR089085 A1 AR 089085A1 AR P120104559 A ARP120104559 A AR P120104559A AR P120104559 A ARP120104559 A AR P120104559A AR 089085 A1 AR089085 A1 AR 089085A1
Authority
AR
Argentina
Prior art keywords
her3
domain
antibodies
growth factor
epidermal growth
Prior art date
Application number
ARP120104559A
Other languages
English (en)
Spanish (es)
Inventor
Paul Garner Andrew
Ettenberg Seth
Anne Reisinger Sprague Elizabeth
Huet Heather
Carsten Silvester Kunz Christian
Haubst Nicole
Elis Winfried
Sheng Qing
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR089085A1 publication Critical patent/AR089085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP120104559A 2011-12-05 2012-12-05 Anticuerpos dirigidos al receptor de factor de crecimiento epidermico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3 AR089085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05

Publications (1)

Publication Number Publication Date
AR089085A1 true AR089085A1 (es) 2014-07-30

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104559A AR089085A1 (es) 2011-12-05 2012-12-05 Anticuerpos dirigidos al receptor de factor de crecimiento epidermico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3

Country Status (16)

Country Link
EP (1) EP2788381A2 (ja)
JP (1) JP2015500830A (ja)
KR (1) KR20140099315A (ja)
CN (1) CN104093742A (ja)
AR (1) AR089085A1 (ja)
AU (1) AU2012349739A1 (ja)
BR (1) BR112014013495A2 (ja)
CA (1) CA2857939A1 (ja)
EA (1) EA201491120A1 (ja)
IL (1) IL232950A0 (ja)
IN (1) IN2014CN04374A (ja)
MX (1) MX2014006731A (ja)
SG (1) SG11201402784WA (ja)
TW (1) TW201331225A (ja)
UY (1) UY34488A (ja)
WO (1) WO2013084151A2 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
AU2015223567B2 (en) * 2014-02-28 2020-09-10 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
MX2018004988A (es) 2015-10-23 2018-11-09 Merus Nv Moleculas de union que inhibe el crecimiento de cancer.
JP6729926B2 (ja) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
JP7203426B2 (ja) * 2016-09-15 2023-01-13 ウニヴェルズィテート シュトゥットガルト Ｈｅｒ３に対する抗原結合タンパク質
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2010242914B2 (en) * 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
PT2719708T (pt) * 2009-11-13 2018-01-16 Daiichi Sankyo Europe Gmbh Material e métodos para tratamento ou prevenção de doenças associadas a her-3
AR080873A1 (es) * 2010-04-09 2012-05-16 Aveo Pharmaceuticals Inc Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
DK2707391T3 (en) * 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3

Also Published As

Publication number Publication date
BR112014013495A8 (pt) 2017-06-13
BR112014013495A2 (pt) 2017-06-13
MX2014006731A (es) 2015-06-04
EP2788381A2 (en) 2014-10-15
CN104093742A (zh) 2014-10-08
CA2857939A1 (en) 2013-06-13
WO2013084151A2 (en) 2013-06-13
IL232950A0 (en) 2014-07-31
KR20140099315A (ko) 2014-08-11
EA201491120A1 (ru) 2015-07-30
TW201331225A (zh) 2013-08-01
UY34488A (es) 2013-07-31
AU2012349739A1 (en) 2014-06-26
SG11201402784WA (en) 2014-06-27
JP2015500830A (ja) 2015-01-08
WO2013084151A3 (en) 2014-01-03
IN2014CN04374A (ja) 2015-09-04

Similar Documents

Publication Publication Date Title
AR089085A1 (es) Anticuerpos dirigidos al receptor de factor de crecimiento epidermico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3
CR20110576A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
IN2014CN04373A (ja)
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
EA201891753A1 (ru) Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
PE20151926A1 (es) Anticuerpos de receptores de antitransferrina y metodos de uso
CA2929984C (en) A t cell or natural killer (nk) cell which co-expresses two chimeric antigen receptors (cars)
CR20150329A (es) Inmunoglobulinas heterodiméricas
WO2015092024A3 (en) Method of engineering multi-input signal sensitive t cell for immunotherapy
TN2012000462A1 (en) Anti-cd40 antibodies
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
CR20130278A (es) Prevención de los efectos adversos causados por dominio de unión específicos cd3
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CO6690769A2 (es) Proteínas de unión a antígenos que se unen al receptor her3, polinucleótidos que los comdifican y composiciones que los contienen, útiles a el tratamiento o profilaxis de varios tipos de cancer
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
NZ608318A (en) Anti-cxcl13 antibodies and methods of using the same
MX2013012393A (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
MX2013013832A (es) Proteínas de unión receptoras fc.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ

Legal Events

Date Code Title Description
FB Suspension of granting procedure